Management of Elevated Parathyroid Hormone (PTH) in Elderly Patients

Initial Diagnostic Workup

The American College of Physicians recommends checking serum calcium, phosphorus, 25-OH vitamin D levels, and kidney function to determine whether elevated PTH represents primary or secondary hyperparathyroidism 1, 2
Measuring serum calcium, both total and ionized, helps distinguish primary from secondary hyperparathyroidism, with elevated or high-normal calcium suggesting primary hyperparathyroidism, and low or low-normal calcium indicating secondary hyperparathyroidism 1
Checking serum phosphorus levels is part of the mineral metabolism assessment 1, 2
Obtaining 25-OH vitamin D levels is essential, as vitamin D deficiency is a common and reversible cause of secondary hyperparathyroidism in elderly patients 1, 2
Assessing kidney function with eGFR and creatinine is crucial, as chronic kidney disease causes PTH elevation early in its course, often before calcium or phosphorus abnormalities appear 1, 2

If vitamin D deficiency is present, the National Kidney Foundation recommends supplementing with cholecalciferol or ergocalciferol to achieve 25-OH vitamin D levels ≥30 ng/mL 3, 1, 2
Ensuring adequate dietary calcium intake is essential, meeting age-related recommended dietary allowances, as low urinary calcium excretion suggests calcium deprivation 3
Rechecking PTH levels every 3 months for 6 months, then every 3-6 months, is necessary to assess response to vitamin D repletion 1, 2
If chronic kidney disease is present, the American Journal of Kidney Diseases suggests considering dietary phosphate restriction and phosphate binders if hyperphosphatemia develops 1, 2
Recognizing that PTH levels between 100-500 pg/mL in CKD patients have insufficient sensitivity and specificity to reliably predict bone disease is crucial 4, 1

The American Journal of Kidney Diseases advises against assuming PTH elevation alone indicates primary hyperparathyroidism, as the calcium level is essential for proper classification 5
Avoid treating with active vitamin D if serum phosphorus exceeds 6.5 mg/dL due to the risk of further elevating phosphorus levels 5
Do not over-suppress PTH in CKD patients, as intact PTH levels below 150 pg/mL are associated with a high incidence of adynamic bone disease 5
Be cautious with calcimimetics in elderly patients, as cinacalcet can cause severe hypocalcemia and QT interval prolongation 3

In non‑dialysis CKD stages 3–4, restrict dietary phosphorus to 800–1,000 mg/day (adjusted for protein needs) when serum phosphorus exceeds 4.6 mg/dL. This helps control PTH elevation. 6
Even if serum phosphorus is within normal limits, a rise in PTH signals early phosphate retention; therefore phosphate restriction should still be implemented in CKD 3–4. 6

Active vitamin D (calcitriol, paricalcitol, doxercalciferol) must not be started when serum calcium is >10.2 mg/dL or serum phosphorus is >6.5 mg/dL, to avoid hypercalcemia and vascular calcification. 7
The same phosphorus threshold (>6.5 mg/dL) is reiterated as a contraindication for any active vitamin D therapy in CKD patients. 7

The K/DOQI guideline recommends a PTH target range of 150–300 pg/mL for patients on dialysis. 8
When a dialysis patient’s PTH is ≈104 pg/mL (below the target range), clinicians should avoid further suppression and aim to maintain the current level rather than intensify therapy. 8

After initiating or increasing vitamin D (nutritional or active), measure serum calcium and phosphorus every 2 weeks for the first month, then monthly thereafter. 7
Intact PTH should be measured monthly for at least 3 months, and thereafter every 3 months once the desired range is achieved. 7

Do not prescribe active vitamin D when serum phosphorus exceeds 6.5 mg/dL (reinforcing the safety threshold). 7
Do not initiate active vitamin D if serum calcium is >10.2 mg/dL (reinforcing the safety threshold). 7